Since NPM1 is recurrently mutated in 27–35% of adult AML [11,12], our finding of endogenously presented HLA ligands from this recurrent, shared mutation in the context of common HLA haplotypes may have future immunotherapeutic applications. Here, NPM1 is linked to acute myeloid leukemia.